Table 3.
Treatment-emergent adverse events occurring in 5% or more of patients (N = 36)
| No. (%) | |||||
|---|---|---|---|---|---|
| Any grade | Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Any events | 36 (100) | 36 (100) | 28 (77.8) | 25 (69.4) | 6 (16.7) |
| General disorders | |||||
| Weight loss | 5 (13.9) | 2 (5.6) | 3 (8.3) | 0 | 0 |
| Cough | 2 (5.6) | 2 (5.6) | 0 | 0 | 0 |
| Urinary tract infection | 2 (5.6) | 1 (2.8) | 1 (2.8) | 0 | 0 |
| Hematological | |||||
| Lymphocyte count decreased | 35 (97.2) | 3 (8.3) | 5 (13.9) | 24 (66.7) | 3 (8.3) |
| White blood cell decreased | 26 (72.2) | 9 (25.0) | 15 (41.7) | 2 (5.6) | 0 |
| Anemia | 25 (69.4) | 21 (58.3) | 4 (11.1) | 0 | 0 |
| Platelet count decreased | 19 (52.8) | 13 (36.1) | 6 (16.7) | 0 | 0 |
| Neutropenia | 17 (47.2) | 9 (25.0) | 8 (22.2) | 0 | 0 |
| Biochemistry | |||||
| Hypocalcaemia | 6 (16.7) | 5 (13.9) | 1 (2.8) | 0 | 0 |
| Hypokalemia | 3 (8.3) | 3 (8.3) | 0 | 0 | 0 |
| Hyponatremia | 3 (8.3) | 2 (5.6) | 1 (2.8) | 0 | 0 |
| Hypoalbuminemia | 3 (8.3) | 2 (5.6) | 1 (2.8) | 0 | 0 |
| Hyperuricemia | 3 (8.3) | 3 (8.3) | 0 | 0 | 0 |
| Blood bilirubin increased | 2 (5.6) | 1 (2.8) | 1 (2.8) | 0 | 0 |
| Gastrointestinal disorders | |||||
| Vomiting | 16 (44.4) | 11 (30.6) | 5 (13.9) | 0 | 0 |
| Nausea | 15 (41.7) | 12 (33.3) | 2 (5.6) | 1 (2.8) | 0 |
| Loss of appetite | 3 (8.3) | 2 (5.6) | 1 (2.8) | 0 | 0 |
| Diarrhea | 2 (5.6) | 2 (5.6) | 0 | 0 | 0 |
| Abdominal distension | 2 (5.6) | 2 (5.6) | 0 | 0 | 0 |
| Constipation | 2 (5.6) | 2 (5.6) | 0 | 0 | 0 |
No grade 5 treatment-emergent adverse events occurred.